Effects of GPR81 agonist on insulin resistance in rats with nonalcoholic fatty liver disease

doi:10.12047/j.cjap.6055.2021.033

Abstract

Abstract: Objective: To investigate the effects of NOD-like receptor protein 3 (NLRP3) signaling pathway on insulin resistance and the intervention of lactic acid receptor G protein-coupled receptor 81 (GPR81) agonist in nonalcoholic fatty liver disease (NAFLD) rats. Methods: Thirty SD male rats were randomly divided into three groups: control group, NAFLD group and GPR81 agonist group, with 10 rats in each group. Nonalcoholic fatty liver rat model was established by high fat diet. The rats in GPR81 agonist group were injected intraperitoneally with GPR81 specific agonist lactate (50 nmol/L) on the basis of nonalcoholic fatty liver model once a week, and the other two groups were injected with the same amount of normal saline for 12 weeks. The levels of liver biochemical indexes, fasting blood glucose, insulin and inflammatory factors in liver homogenate were measured, and the histopathological morphology of liver in each group was observed. The protein expressions of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), cysteinyl aspartate specific proteinase-1 (caspase-1), insulin receptor substrate 1 (IRS-1), Tyr⁴⁶⁵-IRS-1, Ser⁶³⁶-IRS-1, glucose transporter 4 (GLUT4) in liver tissue were detected by Western blot. The mRNA expression levels of NLRP3, ASC, caspase-1, IRS-1 and GLUT4 in liver tissue were detected by qRT-PCR. Results: Compared with the control group, the serum levels of triglyceride (TG), alanine aminotransfease (ALT), aspartate aminotransfease (AST), fasting plasma glucose (FPG), fasting insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA-IR) of NAFLD group were increased significantly (P＜ 0.05). The results of liver histopathology showed that in NAFLD group, there were obvious fatty changes in liver tissue, fat droplets in hepatocytes and inflammatory cell infiltration. And the mRNA and protein expressions of NLRP3, ASC, caspase-1 and the protein expression of Ser⁶³⁶-IRS-1 in NAFLD group were increased significantly, and the contents of interleukin 1β (IL-1β) and interleukin 18 (IL-18) in liver and serum were increased, while the mRNA and protein expressions of IRS-1 and GLUT4 and Tyr⁴⁶⁵-IRS-1 were decreased significantly (P＜0.05). Compared with NAFLD group, the above indexes of GPR81 agonist group were all significantly improved. Conclusion: The activation of NLRP3 signaling pathway mediates the production of inflammatory factors and promotes the development of NAFLD. GPR81 agonist may be a potential treatment for NAFLD.

CLC Number:

R575.5

ZHANG Yu, LU Qing-hua, CAO Hai-fang, ZHANG Sheng-rong, WANG Hu-de. Effects of GPR81 agonist on insulin resistance in rats with nonalcoholic fatty liver disease[J]. CJAP, 2021, 37(4): 354-358.

References 19

[1]	崔桂玉, 白剑, 苗兰英, 等. 丹参对非酒精性脂肪肝Th17细胞及相关细胞因子的影响[J]. 中国应用生理学杂志, 2019, 35(6): 517-522.
[2]	邢英, 李雅丽, 郑嵘炅, 等. 利拉鲁肽对非酒精性脂肪肝大鼠胰岛素抵抗的改善作用[J]. 实用肝脏病杂志, 2017, 20(6): 668-671.
[3]	Lv Y, Gao X, Luo Y, et al. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways[J]. J Nutr Biochem, 2019, 71: 110-121.
[4]	Ranganathan P, Shanmugam A, Swafford D, et al. GPR81, a cell-surface receptor for lactate, regulates intestinal homeostasis and protects mice from experimental colitis[J]. J Immunol, 2018, 200(5): 1781-1789.
[5]	Madaan A, Mathieu NV, Rivera JC, et al. Lactate produced during labor modulates uterine inflammation via GPR81 (HCA1)[J]. Am J Obstet Gynecol, 2017, 216(1): e1-e17.
[6]	Hoque R, Farooq A, Ghani A, et al. Lactate reduces liver and pancreatic injury in toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity[J]. Gastroenterology, 2014, 146(7): 1763-1774.
[7]	韩然, 曾祥梅, 吴小翎. p38丝裂原活化蛋白激酶在大鼠非酒精性脂肪肝中的作用[J]. 重庆医科大学学报, 2016, 41(6): 576-580.
[8]	刘皎皎, 戴玲, 董璐, 等. 虎杖苷对非酒精性脂肪肝的影响及相关分子机制探究[J]. 中国免疫学杂志, 2019, 35(10): 1188-1192.
[9]	Ye FZ, Liu WY, Zheng KI, et al. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2020, 32(1): 80-86.
[10]	张晓, 王慧, 王渊, 等. DPP-4抑制剂作用于非酒精性脂肪肝发病机制的研究进展[J]. 重庆医科大学学报, 2018, 43(12): 1619-1622.
[11]	王锋, 张海峰. 利拉鲁肽联合维生素D对高脂诱导非酒精性脂肪肝小鼠的影响及机制[J]. 中国应用生理学杂志, 2020, 36(3): 71-75.
[12]	邓涛, 龚建平, 何堃. NLRP3基因敲除对非酒精性脂肪性肝炎小鼠的影响[J]. 山东医药, 2019, 59(1): 7-10.
[13]	Cho KW, Cho DH. Telmisartan increases hepatic glucose production via protein kinase Cζ-dependent insulin receptor substrate-1 phosphorylation in HepG2 cells and mouse liver[J]. Yeungnam Univ J Med, 2019, 36(1): 26-35.
[14]	姚骏凯, 高学敏, 李伟, 等. 青钱柳叶对2型糖尿病胰岛素抵抗大鼠骨骼肌INsR/IRS1/PI3K/GLUT4通路的影响[J]. 中华中医药杂志, 2019, 34(1): 86-90.
[15]	王定坤, 陈广, 陆付耳. NLRP3炎症小体与2型糖尿病的研究进展[J]. 生理科学进展, 2014, 45(2): 111-114.
[16]	Chen YN, Qian Q, Yu J. Carbenoxolone ameliorates insulin sensitivity in obese mice induced by high fat diet via regulating the IκB-α/NF-κB pathway and NLRP3 inflammasome[J]. Biomed Pharmacother, 2019, 115: 108868.
[17]	赵乃倩, 荣青峰, 郭娜, 等. 乳酸受体GPR81的研究进展[J]. 生命科学, 2014, 26(11): 1200-1206.
[18]	Wallenius K, Thalén P, Bjrkman JA, et al. Involvement of the metabolic sensor GPR81 in cardiovascular control[J]. JCI Insight, 2017, 2(19): e92564.
[19]	Sun ZR, Han Y, Song SB, et al. Activation of GPR81 by lactate inhibits oscillatory shear stress-induced endothelial inflammation by activating the expression of KLF2[J]. IUBMB Life, 2019, 71(12): 2010-2019.